Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability

Figures & data

Figure 1 Risk factors for benign prostatic hyperplasia progression.^3–7

Abbreviations: IPSS, International Prostate Symptom Score; PSA, prostate-specific antigen.

Figure 2 Milestones of changes in medical management of benign prostatic hyperplasia (BPH).

Figure 3 Comparison of baseline demographics and study designs of MTOPS and CombAT.¹⁹

Abbreviations: AUR, acute urinary retention; BPH, benign prostatic hyperplasia; IPSS, International Prostate Symptom Score; PV, prostate volume; PSA, prostate-specific antigen.
Note: Reprinted with permission from Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–131.¹⁹ Copyright © 2010 Elsevier.

Figure 4 Mean change International Prostate Symptom Score (IPSS) from baseline: primary endpoint in 4-year CombAT trial.

Note: Reprinted with permission from Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–131.¹⁹ Copyright © 2010 Elsevier.

Figure 5 Four-year primary and secondary CombAT endpoints.²¹

Abbreviations: AUR, acute urinary retention; BPH, benign prostatic hyperplasia; IPSS, International Prostate Symptom Score; UTI, urinary tract infection.

Figure 6 CombAT 4-year composite primary endpoint – time to first AUR or BPH surgery.

Note: Reprinted with permission from Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–131.¹⁹ Copyright © 2010 Elsevier.
Abbreviations: AUR, acute urinary retention; BPH, benign prostatic hyperplasia; CI, confidence interval; RRR, relative risk reduction.

Figure 7 CombAT 4-year secondary endpoints – clinical progression.

Notes: Rate based on ITT population; *P < 0.001 versus combination. Reprinted with permission from Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–131.¹⁹ Copyright © 2010 Elsevier.
Abbreviations: AUR, acute urinary retention; BPH, benign prostatic hyperplasia; IPSS, International Prostate Symptom Score; ITT, intention-to-treat; UTI, urinary tract infection.

Figure 8 Description of Patient’s Perception of Study Medicine Questionnaire (PPSM).¹⁴

Note: Seven-point scale (Qs 1 to 11) or ‘yes’, ‘no’ or ‘not sure’ (Q12).

Figure 9 Patient’s Perception of Study Medicine Questionnaire (PPSM) results for questions 11 and 12.

Figure 10 CombAT 4-year incidence of drug-related adverse events.

Note: Reprinted with permission from Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–131.¹⁹ Copyright © 2010 Elsevier.

AndersonJBRoehrbornCGSchalkenJAEmbertonMThe progression of benign prostatic hyperplasia: examining the evidence and determining the riskEur Urol200139439039911306876

 PubMed Web of Science ®Google Scholar

RoehrbornCGDefinition of at-risk patients: baseline variablesBJU Int200697Suppl 2711 discussion 21–2216507046

 PubMed Web of Science ®Google Scholar

RoehrbornCGSiamiPBarkinJThe effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT studyEur Urol201057112313119825505

 PubMed Web of Science ®Google Scholar

NaslundMEaddyMTHogueSLKruepEJShahMBImpact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgeryCurr Med Res Opin200925112663266919757985

 PubMed Web of Science ®Google Scholar

McConnellJDBruskewitzRWalshPThe effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasiaN Engl J Med19983385575639475762

 PubMed Web of Science ®Google Scholar